• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Says This Basic Materials Stock Is 'Too Dicey,' Shares His Take On Arista Networks

    5/24/24 9:11:57 AM ET
    $ANET
    $DJT
    $LLY
    $SGML
    Computer Communications Equipment
    Telecommunications
    Computer Software: Programming Data Processing
    Technology
    Get the next $ANET alert in real time by email

    On CNBC's “Mad Money Lightning Round,” Jim Cramer said Arista Networks, Inc. (NYSE:ANET) reported an “unbelievable” quarter, and the company's CEO Jayshree Ullal is doing a “terrific” job.

    He added, “All of these stocks are a little volatile right now, but I think you want to own it and buy it into the volatility.”

    On May 7, Arista Networks posted strong first-quarter earnings and issued upbeat guidance. The company’s board of directors authorized an additional $1.2 billion stock repurchase program.

    Cramer said Trump Media & Technology Group Corp. (NASDAQ:DJT) is the most volatile stock he has ever come across. He added, “That is a wild one, I don't know. I mean, it depends on the trial, it depends on the money flows.”

    On May 20, Trump Media and Technology Group reported a loss of over $300 million last quarter, marking its first earnings report as a publicly traded company.

    When asked about Sony Group Corporation (NYSE:SONY), he said, “I just like the stock as is, and it's been weighed down by the takeover talk.”

    On May 14, Sony reported better-than-expected fourth-quarter financial results. The company announced Hideaki Nishino and Hermen Hulst will succeed former PlayStation boss Jim Ryan as co-CEOs, effective June 1, 2024.

    The “Mad Money” host said Sigma Lithium Corporation (NASDAQ:SGML) is “too dicey” for him.

    On May 16, Sigma Lithium posted a first-quarter loss of 6 cents per share, versus a year-ago loss of 21 cents per share.

    Cramer recommended Eli Lilly and Company (NYSE:LLY), adding, “And let's hope it comes in so we can buy more.”

    On Tuesday, Eli Lilly announced that Chinese regulators have approved its diabetes drug tirzepatide.

    Price Action:

    • Arista Networks shares fell 4.8% to settle at $301.42 on Thursday.
    • Sigma Lithium shares fell 4.2% to close at $15.72 on Thursday.
    • Trump Media & Technology Group shares slipped 1.5% to settle at $43.91.
    • Eli Lilly shares gained 0.7% to settle at $808.45 on Thursday.
    • Sony shares fell 0.6% to settle at $80.80 during Thursday's session.

    Read Next: Top 5 Tech Stocks That Could Lead To Your Biggest Gains This Month

    Image: Shutterstock

    Get the next $ANET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANET
    $DJT
    $LLY
    $SGML

    CompanyDatePrice TargetRatingAnalyst
    Sigma Lithium Corporation
    $SGML
    2/3/2026$14.00Underperform → Neutral
    BofA Securities
    Sigma Lithium Corporation
    $SGML
    1/23/2026Hold → Buy
    Canaccord Genuity
    Sigma Lithium Corporation
    $SGML
    1/16/2026Buy → Hold
    Canaccord Genuity
    Sigma Lithium Corporation
    $SGML
    1/8/2026$13.00Neutral → Underperform
    BofA Securities
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Arista Networks Inc.
    $ANET
    1/5/2026$159.00Neutral → Overweight
    Piper Sandler
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    More analyst ratings

    $ANET
    $DJT
    $LLY
    $SGML
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Pres LLY Oncology&HdCorpBD Van Naarden Jacob was granted 4,866 shares, increasing direct ownership by 22% to 26,626 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:25:13 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $DJT
    $LLY
    $SGML
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sigma Lithium upgraded by BofA Securities with a new price target

    BofA Securities upgraded Sigma Lithium from Underperform to Neutral and set a new price target of $14.00

    2/3/26 6:51:05 AM ET
    $SGML
    Metal Mining
    Basic Materials

    Sigma Lithium upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Sigma Lithium from Hold to Buy

    1/23/26 12:02:57 PM ET
    $SGML
    Metal Mining
    Basic Materials

    Sigma Lithium downgraded by Canaccord Genuity

    Canaccord Genuity downgraded Sigma Lithium from Buy to Hold

    1/16/26 8:56:28 AM ET
    $SGML
    Metal Mining
    Basic Materials

    $ANET
    $DJT
    $LLY
    $SGML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and Secretary Glabe Scott bought $10,465 worth of shares (1,000 units at $10.46), increasing direct ownership by 0.31% to 326,236 units (SEC Form 4)

    4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)

    11/19/25 8:48:25 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $DJT
    $LLY
    $SGML
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Miners Win as China's Export Ban Triggers 54-Nation Pact Reshaping Critical Minerals

    Issued on behalf of GoldHaven Resource Corp. VANCOUVER, BC, Feb. 6, 2026 /PRNewswire/ -- Equity Insider News Commentary — The global supply map just broke. China restricted critical tungsten exports to Japan in January[1], causing the United States to counter by rallying 54 nations and launching $30 billion in strategic financing[2]. This geopolitical chess match is rapidly de-risking domestic production. It position GoldHaven Resources Corp. (CSE:GOH) (OTCQB:GHVNF), Sigma Lithium (NASDAQ:SGML) (TSXV:SGML) , Berkshire Hathaway (NYSE:BRK) (NYSE:BRK), Rio Tinto (NYSE:RIO), and Talon Metals (TSX:TLO) (OTCID: TLOFD) at the forefront of a massive capital rotation. This is a structural pivot, no

    2/6/26 1:00:00 PM ET
    $RIO
    $SGML
    $BRK
    Metal Mining
    Basic Materials

    $ANET
    $DJT
    $LLY
    $SGML
    SEC Filings

    View All

    SEC Form 6-K filed by Sony Group Corporation

    6-K - Sony Group Corp (0000313838) (Filer)

    2/5/26 6:06:51 AM ET
    $SONY
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 6-K filed by Sony Group Corporation

    6-K - Sony Group Corp (0000313838) (Filer)

    2/5/26 6:06:15 AM ET
    $SONY
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 6-K filed by Sony Group Corporation

    6-K - Sony Group Corp (0000313838) (Filer)

    2/5/26 6:05:38 AM ET
    $SONY
    Consumer Electronics/Appliances
    Consumer Staples

    $ANET
    $DJT
    $LLY
    $SGML
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $DJT
    $LLY
    $SGML
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ThredUp Appoints Financial Governance Leader Kelly Bodnar Battles to Board of Directors and Audit Committee Chair

    Financial Leader to Bolster Oversight During Period of Accelerated Growth ThredUp (NASDAQ:TDUP, LTSE: TDUP)), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Kelly Bodnar Battles to its Board of Directors, with the appointment becoming effective on December 1, 2025. Upon the effective date, Battles will assume the role of Audit Committee Chair. This appointment reinforces ThredUp's continued commitment to strengthening its financial governance as the company accelerates its growth and transformation into an AI-first resale marketplace. This press release features multimedia. View the full release here: https://www.busines

    11/17/25 4:05:00 PM ET
    $ANET
    $TDUP
    Computer Communications Equipment
    Telecommunications
    Catalog/Specialty Distribution
    Consumer Discretionary

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $DJT
    $LLY
    $SGML
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANET
    $DJT
    $LLY
    $SGML
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trump Media & Technology Group Corp.

    SC 13G/A - Trump Media & Technology Group Corp. (0001849635) (Subject)

    11/14/24 9:53:48 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Arista Networks Inc.

    SC 13G/A - Arista Networks, Inc. (0001596532) (Subject)

    11/12/24 1:23:45 PM ET
    $ANET
    Computer Communications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by Arista Networks Inc.

    SC 13G/A - Arista Networks, Inc. (0001596532) (Subject)

    11/4/24 11:19:36 AM ET
    $ANET
    Computer Communications Equipment
    Telecommunications